Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Itacnosertib - Sumitomo Pharma America

Next Previous
Drug Profile

Itacnosertib - Sumitomo Pharma America

Alternative Names: Itacnosertib - Sumitomo Dainippon Pharma Oncology; TP-0184

Latest Information Update: 19 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tolero Pharmaceuticals
  • Developer Sumitomo Pharma America
  • Class Amines; Antianaemics; Antineoplastics; Piperazines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action ACVR1 protein inhibitors; Transforming growth factor beta type I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia
  • Discontinued Anaemia

Most Recent Events

  • 30 Mar 2023 Sumitomo Pharma Oncology terminates a phase I/II trial in Anaemia (Treatment-resistant) in USA (PO) due to limitations imposed by the COVID pandemic and the competitive landscape for myelodysplastic syndrome (NCT04623996)
  • 10 Dec 2022 Pharmacodynamics data from a preclinical study in Acute myeloid leukemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 24 May 2022 Discontinued - Phase-I/II for Anaemia (Treatment-resistant) in USA (PO) (Sumitomo Pharma pipeline, May 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top